Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment
Biomedicines, 2022 Two granulysin (GRNLY) based immunotoxins were generated, one containing the scFv of the SM3 mAb (SM3GRNLY) and the other the scFv of the AR20.5 mAb (AR20.5GRNLY). These mAb recognize different amino acid sequences of aberrantly O-glycosylated MUC1, also
Patricia Guerrero-Ochoa +2 more
exaly +3 more sources
Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer [PDF]
Frontiers in Molecular BiosciencesDespite the efforts of researchers to develop new treatments for small cell lung cancer (SCLC), achieving effective treatment has not yet happened. Targeted therapy utilizing delta-like ligand 3 (DLL3), which is highly expressed in SCLC patients, holds ...
Mohammad Hossein Ataee +4 more
doaj +2 more sources
Frontiers in Immunology, 2020 Immunotoxins are cytolytic fusion proteins developed for cancer therapy, composed of an antibody fragment that binds to a cancer cell and a protein toxin fragment that kills the cell.
Ronit Mazor, Ira Pastan, Mazor Ronit
exaly +3 more sources
Immunotoxins: The Role of the Toxin [PDF]
Toxins, 2013 Immunotoxins are antibody-toxin bifunctional molecules that rely on intracellular toxin action to kill target cells. Target specificity is determined via the binding attributes of the chosen antibody. Mostly, but not exclusively, immunotoxins are purpose-
David FitzGerald, Antonella Antignani
doaj +3 more sources
The Use of Bacteria and Their Toxins as Antitumor Agents: Present and Future [PDF]
MicroorganismsCancer remains one of the leading causes of morbidity and mortality worldwide, and despite major advances in surgery, chemotherapy, radiotherapy, and immunotherapy, important therapeutic limitations persist, including systemic toxicity, therapeutic ...
Luz María Ibarra-Velázquez +5 more
doaj +2 more sources
Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma [PDF]
ToxinsSarcomas are very complex and clinically challenging mesenchymal tumors. Although the standard therapeutic approach has improved the 5-year survival rate, many patients experience local relapses and/or distant metastases.
Giulia Calafato +3 more
doaj +2 more sources
Heterogeneity of Cancer-Associated Fibroblasts and Precision Targeting Strategies for Cancer Therapy. [PDF]
Thorac CancerCAFs orchestrate tumor immunosuppression through spatially organized ECM remodeling, cytokine signaling, and metabolic reprogramming. Targeting CAFs requires a shift from marker‐based depletion to functional state and niche‐specific intervention. ABSTRACT Immune checkpoint blockade (ICB) has transformed cancer therapy, but its effect is often limited ...
Wang Y +4 more
europepmc +2 more sources
Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH [PDF]
Journal of Translational Medicine, 2023 Background Immunotoxins are antibody-toxin conjugates that bind to surface antigens and exert effective cytotoxic activity after internalization into tumor cells.
Xiaoyu Liu +15 more
doaj +2 more sources
Macrophage-Targeted Therapy: CD64-Based Immunotoxins for Treatment of Chronic Inflammatory Diseases
Toxins, 2012 Diseases caused by chronic inflammation (e.g., arthritis, multiple sclerosis and diabetic ulcers) are multicausal, thus making treatment difficult and inefficient. Due to the age-associated nature of most of these disorders and the demographic transition
Dmitrij Hristodorov +2 more
exaly +3 more sources
Immunotoxins: From Design to Clinical Application
Biomolecules, 2021 The Special Issue of Biomolecules entitled “Immunotoxins, From Design to Clinical Application” contains seven reviews related to immunotoxins [...]
Robert J. Kreitman, Ira Pastan
doaj +1 more source